AI Automated Translation.

Font Size

Share

Daewoong Pharmaceutical and Tion Lab Receive Approval for Phase 1 Clinical Trial of Once-Monthly Obesity Treatment Candidate in South Korea

Daewoong Pharmaceutical and Tion Lab Receive Approval for Phase 1 Clinical Trial of Once-Monthly Obesity Treatment Candidate in South Korea

Long-acting injectable based on semaglutide, 'TION-L002', Enters Phase 1 Clinical Trials in South Korea

'TION-L002,' jointly developed by Daewoong Pharmaceutical and Tion Lab Therapeutics, and each company's CI /Photo=Daewoong Pharmaceutical
'TION-L002,' jointly developed by Daewoong Pharmaceutical and Tion Lab Therapeutics, and each company's CI /Photo=Daewoong Pharmaceutical

Daewoong Pharmaceutical announced on the 19th that it has received approval for the Investigational New Drug (IND) application for a Phase 1 clinical trial in South Korea of 'TION-L002,' a once-monthly long-acting obesity treatment candidate being jointly developed with Tion Lab Therapeutics.

TION-L002 is a long-acting injectable under development based on semaglutide (product name Wegovy), a glucagon-like peptide-1 (GLP-1) receptor agonist used for obesity treatment. It aims to reduce the burden of medication on patients and enhance treatment convenience by extending the dosing interval of existing weekly semaglutide formulations to once a month.

Obesity is a chronic disease requiring long-term treatment and management, making not only therapeutic efficacy but also patient medication convenience and treatment adherence important. TION-L002 is being developed with the goal of reducing the annual number of injections from 52 to 12 compared to existing weekly formulations.

The two companies plan to evaluate the safety and pharmacokinetic properties of TION-L002 in Phase 1 clinical trials and confirm the development potential of the long-acting formulation through comparison with a control drug. Based on this, they intend to identify global collaboration partners and pursue entry into overseas markets through joint development.

The core competitiveness of TION-L002 lies in its design, which combines the proprietary drug delivery technologies held by Daewoong Pharmaceutical and Tion Lab Therapeutics to precisely control the release rate and duration of the drug.

Daewoong Pharmaceutical's 'CURE®' platform is a technology that uses an 'Inlet Nozzle' process to make drug particle sizes uniform, allowing the drug to be released at a constant rate over a long period. Tion Lab Therapeutics' 'Quject®Sphere' platform is a technology that coats the surface of drug particles with a specialized composition to prevent the drug from being released all at once immediately after injection.

The two companies are developing a formulation that combines these two technologies to control initial drug release while maintaining a constant release rate over a long period. Through this, they aim to realize once-monthly dosing of semaglutide and secure stable drug release properties.

Park Seong-su, CEO of Daewoong Pharmaceutical, stated, "Based on the data secured in domestic clinical trials, we will expand global partnerships and accelerate development to provide more convenient treatment options to patients worldwide."

Meanwhile, Daewoong Pharmaceutical is also jointly developing 'DWRX5003,' a semaglutide patch-type obesity treatment, with Daewoong Therapeutics.

"This article was translated using AI and may differ slightly from the original."